Eflornithine (DFMO) |
| カタログ番号GC30283 |
エフロルニチン (DFMO) は、酵素オルニチン デカルボキシラーゼの特異的で不可逆的な阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 70052-12-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Eflornithine(DFMO) inhibits polyamine biosynthesis by irreversible inhibition of ornithine decarboxylase(ODC). It is a chemotherapeutic protectant that blocks angiogenesis. Its biological half-life is 8 hours[1-2].
Eflornithine (0.5 mM DFMO;72h) sensitizes homologous recombination (HR)-Competent Ovarian Cancer Cells to Rucaparib [3]. Combination of Eflornithine (1 mM; 48 h) and Thymoquinone (TQ) significantly reduced cell viability and resulted in significant synergistic effects on apoptosis when compared to either Eflornithine or TQ alone in Jurkat cells [4]. Eflornithine (5 mM;72h) treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G (1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198[5].
Eflornithine (1% w/v in the drinking water; 48-72 h) alone markedly increases survival of pancreatic tumor-bearing mice in contrast with GW5074 across multiple dosing and tumor seeding strategies [6]. The Kras(G12D/+) mice fed Eflornithine at 0.1% and 0.2% in the diet showed a significant inhibition of pancreatic ductal adenocarcinoma (PDAC) incidence compared with mice fed control diet [7].
References:
[1]. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Eflornithine. 2021 Dec 20. PMID: 29999676.
[2]. Kang CN, Shah M, et,al. Hair Removal Practices: A Literature Review. Skin Therapy Lett. 2021 Sep;26(5):6-11. PMID: 34524781.
[3]. El Naggar O, Doyle B, et,al. Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells. Med Sci (Basel). 2022 May 26;10(2):28. doi: 10.3390/medsci10020028. PMID: 35736348; PMCID: PMC9230675.
[4]. Alhosin M, Razvi SSI, et,al. Thymoquinone and Difluoromethylornithine (DFMO) Synergistically Induce Apoptosis of Human Acute T Lymphoblastic Leukemia Jurkat Cells Through the Modulation of Epigenetic Pathways. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820947489. doi: 10.1177/1533033820947489. PMID: 32912061; PMCID: PMC7488875.
[5]. Koomoa DL, Geerts D, et,al. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol. 2013 Apr;42(4):1219-28. doi: 10.3892/ijo.2013.1835. Epub 2013 Feb 21. PMID: 23440295; PMCID: PMC3622674.
[6]. Nakkina SP, Gitto SB, et,al. DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment. Int J Mol Sci. 2021 Dec 7;22(24):13175. doi: 10.3390/ijms222413175. PMID: 34947972; PMCID: PMC8706739.
[7]. Mohammed A, Janakiram NB, et,al. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Cancer Prev Res (Phila). 2014 Dec;7(12):1198-209. doi: 10.1158/1940-6207.CAPR-14-0176. Epub 2014 Sep 23. PMID: 25248858; PMCID: PMC4310684.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *